logo
Plus   Neg
Share
Email

ABN Amro Q2 Profit Up 1%; Says Focused On Targets - Quick Facts

Dutch bank ABN AMRO (ABNYY.PK) reported second-quarter net profit of 693 million euros, up 1 percent from 688 million euros in the same period last year.

The company noted that the latest quarter's results reflected solid operational performance and moderate impairments. The results included a pre-tax provision of 114 million euros for a customer due diligence remediation programme at Retail Banking.

Operating result for the quarter declined 1 percent to 1.01 billion euros from 1.03 billion euros last year.

Operating income increased 1 percent to 2.32 billion euros from the prior year's 2.29 billion euros.

ABN Amro said it's interim dividend has been set at 0.60 euros per share, representing a pay-out of 50 percent of half-year profit.

Looking ahead, Kees van Dijkhuizen, CEO of ABN Amro said, "We are taking action by focusing on margins, developing revenue opportunities and strict cost discipline. We remain focused on our targets in a challenging environment."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Novacyt S.A. said it is seeing unprecedented demand for the novel coronavirus or COVID-19 diagnostic test kit developed by Primerdesign, the company's molecular diagnostics division based in the UK. As of March 27, Primerdesign has sold and received orders for more than 17.8 million pounds of its CE-Mark COVID-19 tests. Novacyt is currently selling its COVID-19 test to more than 80 countries. The U.S. Food and Drug Administration has issued an Emergency Use Authorization to allow anti-malaria drugs hydroxychloroquine sulfate and chloroquine phosphate donated to the Strategic National Stockpile as possible treatments for coronavirus (COVID-19) patients. This is the first EUA for a drug related to the COVID-19 response. Gilead Sciences Inc. said it is transitioning to "expanded access programs" from "compassionate use" programs for its experimental anti-coronavirus drug, remdesivir. The company noted that the expanded access will allow hospitals or physicians to apply for emergency use of remdesivir for multiple severely ill patients at one time, as they struggle to deal with the COVID-19 or coronavirus pandemic.
Follow RTT
>